Tempus, a provider in artificial intelligence (AI) and precision medicine, has entered a multi-year, strategic collaboration with Pfizer to further AI and machine learning-driven efforts in therapeutic development. The collaboration aims to more precisely gather insights that will inform novel drug discovery and development in oncology.
Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights for therapeutic development in oncology. Pfizer also has access to Tempus’ capabilities that support therapeutic R&D, to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.
“Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics,” said Eric Lefkofsky, Founder and CEO of Tempus. “This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”
Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights for therapeutic development in oncology. Pfizer also has access to Tempus’ capabilities that support therapeutic R&D, to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.
“Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics,” said Eric Lefkofsky, Founder and CEO of Tempus. “This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”
